Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Scientific Reports|December 9, 2022
Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritisHadas Stiebel-Kalish, Kerstin Rubarth, Karny Shouchane-Blum, et al.
Plos One|December 7, 2023
Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosisAdi Wilf-Yarkoni, Kristina Feldmann, Kerstin Rubarth, et al.
Bone Marrow Transplantation|April 20, 2004
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapyJ Czyz, R Szydlo, W Knopinska-Posluszny, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter studyJ Walewski, E Kraszewska, O Mioduszewska, et al.
Leukemia & Lymphoma|June 1, 1996
2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemiaT Robak, M Błasińska-Morawiec, E Krykowski, et al.
Blood|October 7, 2000
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trialT Robak, J Z Bloński, M Kasznicki, et al.
British Journal of Haematology|February 26, 2000
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patientsT Robak, J Z Bloński, M Kasznicki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patientsJ Czyz, R Dziadziuszko, W Knopinska-Postuszuy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody diseaseItay Lotan, John J Chen, Yael Hacohen, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Pageof 18